Curated News
By: NewsRamp Editorial Staff
July 21, 2026
Greenwich LifeSciences Advances Phase 3 Breast Cancer Immunotherapy Trial
TLDR
- Greenwich LifeSciences' GLSI-100 shows 70-80% recurrence reduction, potentially offering a competitive edge in breast cancer immunotherapy.
- Phase 3 FLAMINGO-01 trial expands to 2000 patients, includes all HLA types, and continues after DSMB review, strengthening study design.
- This immunotherapy aims to prevent breast cancer recurrence, improving survival and quality of life for patients worldwide.
- GP2 targets HER2 protein expressed in 75% of breast cancers, showing promise beyond traditional treatments.
Impact - Why it Matters
This news matters because it highlights progress in the fight against breast cancer recurrence. If successful, GLSI-100 could offer a new treatment option for patients with HER2-expressing breast cancers, potentially reducing the risk of recurrence by 70-80%. The trial's expansion to include all HLA types and increase enrollment may accelerate development and broaden the patient population that could benefit. For investors, the positive DSMB recommendation and regulatory support signal reduced risk and potential for future approval.
Summary
Greenwich LifeSciences (NASDAQ: GLSI) has announced a significant update for its Phase 3 FLAMINGO-01 trial, which is evaluating GLSI-100, an immunotherapy designed to prevent breast cancer recurrence. The Data Safety Monitoring Board recommended that the trial continue without modification following its May 2026 review. Additionally, regulatory authorities in the U.S. and Europe have supported planned protocol changes, including expanding enrollment to up to 2,000 patients, increasing enrollment rates by including all HLA types, and maintaining enrollment through interim analyses to strengthen the study design and boost the probability of success.
To date, more than 1,500 patients have been screened across approximately 170 to 180 clinical sites in 11 countries, with plans to expand into additional European markets, the U.K., and Canada. Preliminary data from the fully enrolled open-label non-HLA-A*02 arm continues to show a 70% to 80% reduction in breast cancer recurrence following the primary immunization series. However, the company emphasizes that these findings are preliminary and not predictive of the final Phase 3 results.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on developing GP2, an immunotherapy to prevent breast cancer recurrences in patients who have undergone surgery. GP2 targets the HER2 protein, which is expressed in 75% of breast cancers. The FLAMINGO-01 trial is a critical step toward potentially bringing this therapy to market. For more details, the full press release is available at https://ibn.fm/elLnN.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Greenwich LifeSciences Advances Phase 3 Breast Cancer Immunotherapy Trial
